COR Stock Analysis: Buy, Sell, or Hold?

COR - Cencora, Inc.

WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES
$318.04
3.35 (1.06%) ▲
5d: +1.34%
30d: +4.25%
90d: +19.82%
WAIT
LOW Confidence
Protect Your COR Gains
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026 0d

Get Alerted When COR Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
â„šī¸ NEUTRAL: COR is fairly priced but lacks strong directional signals. At -0.9% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$464.91
Based on 7.4% avg growth
INTRINSIC VALUE TODAY
$288.67
Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.5x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: COR is currently trading at $318.04, which is considered slightly high relative to its 30-day fair value range of $304.38 to $320.32. The stock's valuation (Forward PE: 16.1) is in line with its historical norms (16.5). Remarkably, the market is currently pricing in an annual earnings decline of 0.9% over the next few years. This pessimistic expectation contrasts with the company's recent 11.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.

Technical Outlook: Technically, COR is showing sideways momentum. Immediate support is located at $302.01, while resistance sits at $333.95.

Market Sentiment: The stock scores a mixed 47/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $369.31 (+16.1%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position SLIGHTLY HIGH
Historical Trading Range $304.38 - $320.32
Company Quality Score 52/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 62.9%

Protect Your Profits

Holding COR? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

  • NEUTRAL: Mixed technical signals (47/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading below Wall St target ($369.31)
  • WARNING: Composite score 52/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $304.38 - $320.32
Current vs Trading Range SLIGHTLY HIGH

Support & Resistance Levels

Support Level $302.01
Resistance Level $333.95
Current Trend Sideways
Technical data as of Aug 21, 2026

Fundamental Context

Forward P/E (Next Year Est.) 16.07
Wall Street Target $369.31 (+16.1%)
Revenue Growth (YoY) 5.1%
Earnings Growth (YoY) 11.9%
Profit Margin 0.8%
Valuation Discount vs History -0.9% cheaper
PE vs Historical 16.1 vs 16.5 FAIR
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): -0.9% (market-implied from PE analysis)
1-Year Target $315.18 (-1%)
2-Year Target $312.34 (-2%)
3-Year Target $309.53 (-3%)
3-Yr Target (if PE normalizes) (PE: 16→17) $317.77 (0%)
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 20.1, Growth: 10.7%) $539.01 (+70%)
Base: (SPY PE: 16.1, Growth: 10.7%) $431.64 (+36%)
Bear: (PE: 13.7, Growth: 10.7%) $366.90 (+15%)
📈 Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (24x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 23.54 | Current EPS (TTM): $13.37
Bull Case $512.33 (+61%)
Analyst growth 48.0%, PE expands to 25.9
Base Case $465.75 (+46%)
Market implied 48.0%, PE stable at 23.5
Bear Case $213.99 (-33%)
Severe decline -20.0%, PE contracts to 20.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡 Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 16.1 to 16.5
Stabilization Target: $326.50 (+2.7%)
PE Expansion Potential: +2.7%
Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit
bloggers & journalists: you are free to use our charts with attribution.
Last updated: August 23, 2026 7:13 AM ET
Data refreshes hourly during market hours. Next update: 8:13 AM
đŸ”Ĩ Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna SELL 2026-03-30
Ro Khanna SELL 2026-03-23

Unlock Insider Activity

See real-time buying/selling by company executives for COR.

Create Free Account

Already have an account? Log In

Top Rated Medical Distribution Stocks

Top-rated stocks in Medical Distribution by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
MCK
McKesson Corporation
STRONG BUY
17 analysts
$991 52 HOLD
CAH
Cardinal Health Inc
BUY
17 analysts
$271 51 HOLD
HSIC
Henry Schein Inc
HOLD
16 analysts
$98 40 SELL
QIPT
Quipt Home Medical Corp
STRONG BUY
5 analysts
$4 52 HOLD
OMI
Owens & Minor Inc
HOLD
6 analysts
$6 46 HOLD

Advanced COR Option Strategies

Professional options setups generated by AI based on today's COR price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for COR

COR Technical Chart COR Price Prediction COR Earnings Date COR Investment Advisor COR Fair Price Analyzer COR Options Advisor COR Options Chain COR Options Analysis COR Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals